| Literature DB >> 35058724 |
Yeye Hu1, Yang He1, Zhiqiang Niu1, Ting Shen1, Ji Zhang1, Xinfeng Wang1, Weicheng Hu1, Jae Youl Cho2.
Abstract
Panax polysaccharides are biopolymers that are isolated and purified from the roots, stems, leaves, flowers, and fruits of Panax L. plants, which have attracted considerable attention because of their immunomodulatory activities. In this paper, the composition and structural characteristics of purified polysaccharides are reviewed. Moreover, the immunomodulatory activities of polysaccharides are described both in vivo and in vitro. In vitro, Panax polysaccharides exert immunomodulatory functions mainly by activating macrophages, dendritic cells, and the complement system. In vivo, Panax polysaccharides can increase the immune organ indices and stimulate lymphocytes. In addition, this paper also discusses the membrane receptors and various signalling pathways of immune cells. Panax polysaccharides have many beneficial therapeutic effects, including enhancing or activating the immune response, and may be helpful in treating cancer, sepsis, osteoporosis, and other conditions. Panax polysaccharides have the potential for use in the development of novel therapeutic agents or adjuvants with beneficial immunomodulatory properties.Entities:
Keywords: Composition; Immunomodulatory; Membrane receptor; Panax polysaccharide; Signalling pathway
Year: 2021 PMID: 35058724 PMCID: PMC8753523 DOI: 10.1016/j.jgr.2021.06.003
Source DB: PubMed Journal: J Ginseng Res ISSN: 1226-8453 Impact factor: 6.060
Source and Structure of Polysaccharides From Panax Species
| Name | Source | Molecular weight/Da | Property | Monosaccharide composition | Structure | Ref. | |
|---|---|---|---|---|---|---|---|
| WGFPN | flower | 1.1 × 104 | neutral | Gal: Ara: Glc: Man = 78:14.3:5.2:2.5 | (1→4)-β-D-galactan and (1→6)-β-D-galactan. | [ | |
| WGPN | root | neutral | Glc: Gal: Ara = 95.3:3.3:1.3 | Starch-like glucans | [ | ||
| FGWP | root | 6.4 × 105 | Gal: Ara: Glc: Rha: GalA = 9.2:10.1:60.6:1.8:17.8 | significantly higher protein content | [ | ||
| FGEF-C | root | Gal: Ara: Glc: Rha: GalA = 10.4:10.5:62.2:2.1:14.3 | relatively high amounts of glucose | ||||
| FGEF-A | root | Gal: Ara: Glc: Rha: GalA = 12.6:10.9:50.9:1.8:23.1 | significantly higher ratios of arabinose, galactose, and galacturonic acid, and lower ratios of glucose | ||||
| FGEF-CA | root | 6.4 × 105 | Gal: Ara: Glc: Rha: GalA = 16.5:11.4:45.8:3.2:22.3 | contained high amounts of rhamnose, arabinose, galactose, and galacturonic acid, with low amounts of glucose | |||
| RGP1 | root | neutral | Ara:Glc:Gal = 0.02:0.88:0.1 | backbones composed of glucose | [ | ||
| RGP2-1 | root | 2.16 × 104 | neutral | Rha:Ara:Glc:Gal = 0.02:0.1:0.77:0.11 | backbones composed of glucose | ||
| NGP | root | 5.04 × 105 | neutral | Glu | O-α-(1→6)-D-Glucan | [ | |
| GPNE-I | root | 8.03 × 104 | neutral | Glc = 1 | a heteropolysaccharide consisting mainly of a glucan domain and type I and II arabinogalactans (AG-I and AG-II) | [ | |
| GPNE-II | root | 3.15 × 104 | neutral | Glc:Gal:Ara = 7.0:1.9:1.0 | a glucan consisting of (1→4)-α-D- Glcp backbone and (1→3)-α-D-Glcp and (1→6)-α-D-Glcp branches. | ||
| GS-P | leave | 1.02 × 104 | acidic | Rha: Fuc: Ara: Gal: GalA = 1.02: 0.31: 1.44: 1.18: 3.73 | pectic polysaccharide consisting of 15 different monosaccharides, with an RG-II polysaccharide component | [ | |
| GFP1 | fruit | 1.4 × 105 | acidic | Rha: Ara: Gal: Glc = 1.1: 3.2: 6.1: 2.0 | backbone (1→ 6)-linked-Galp, (1→3,6)-linked-Galp and (1→3,6)-linked-Glcp residues, with terminal (1→)-linked-Ara for -Rhap attached to O-3 position of (1→3,6)-linked-Galp and (1→3,6)-linked-Glcp | [ | |
| WGPA-2-RG | root | 1.1 × 105 | acidic | Ara: Gal: Glc: Rha: GalA: GlcA = 40.9:44.4:2.9:4.1:5.3:2.0 | arabinogalactans containing RG-I domains | [ | |
| WGPA-UH-N1 | root | 1.7 × 104 | acidic | Glc = 97.5 | α-(1→6)-D-Glucan | [ | |
| RG-CW-EZ-CP-8 | root | 1.47 × 105 | Ara: Fuc: Rha: Man: Glc: Gal: GlcA: GalA = 64.3: 0.1:1.6: 1.3: 9.8: 10.3: 12.3: 0.4 | Ara-rich polysaccharide such as arabinan or arabinogalactan backbone partly branched with acidic polymers | [ | ||
| RG-CW-EZ-CP-4 | root | 1.41 × 105 | acidic | Ara: Fuc: Rha: Man: Glc: Gal: GlcA: GalA = 19.8: 0.3: 4.2: 1.6: 4.0: 29.9: 38.6: 1.7 | pectic-like polysaccharide mainly composed of linear galacturonan as well as relatively small amount of galactan, arabinan, and possibly arabinogalactan | ||
| RGAP | root | acidic | acidic sugars: neutral sugars = 56.9:28.3 | [ | |||
| Ginsan | root | 1.5 × 105 | acidic | glucopyranoside: fructofuranoside = 5:2 | composed of α-(1→6) glucopyranoside and β-(2→6) fructofuranoside | [ | |
| APG | root | acidic | [ | ||||
| GMP | marc | 1.238 × 104 | Gal: Ara: Glc: Rha = 22.6:21.9:14.8:5.8 | pectic-like polysaccharide | [ | ||
| PGP-SL | stem leave | [ | |||||
| PPQ | root | 5.4 × 104 | netural | Glc: Gal = 2.1:1 | homogeneous glucogalactan | [ | |
| AGC1 | seed | 5.2 × 103 | netural | Gal: Ara: Xyl: Glc: Rha: Man = 60.093:19.165:11.363:6.298: 1.548: 0.79 | arabinogalactan type II polysaccharides with a highly branched galactan 3-β-D-Galp residues, short side chains of 6-β-D-Galp residues | [ | |
| PPQN | root | 3.1 × 103 | netural | Glc: Gal = 1:1.15 | glucogalactan a neutral polysaccharide | [ | |
| WPS-1 | root | 1.54 × 106 | netural | Ara: Rha: Man: Gal: Glc = 21.1:2.3:2.6:18.7:55.2 | consisting mainly of (1→6)-α-d-Glcp and (1→5)- α-L-Araf | [ | |
| WPS-2 | root | 1.41 × 104 | netural | Ara: Rha: Man: Gal: Glc = 27.9:1.7:2.9:20.7:46.8 | |||
| SPS-1 | root | 3.62 × 105 | acidic | Ara: Xyl: Man: Gal: Glc: GalA: GlcA = 22.3:6.9:9.2:28.6:15.9:13.6:3.5 | consisting mainly of (1→6)- α-d-Glcp, (1→4)-α-D-Manp, (1→5)- α-L-Araf, β-D-Galp and β-D-xylose. SPS-2 and SPS-3 contained O-acetyl groups; WPS-1 and SPS-3 contained (1→4)- β-D-Rhap | ||
| SPS-2 | root | 9.7 × 106 | acidic | Ara: Xyl: Man: Gal: Glc: GalA: GlcA = 14.2:5.3:7.9:22.5:25.3:16.9:7.9 | |||
| SPS-3 | root | 5.12 × 105 | acidic | Ara: Rha: Xyl: Man: Gal: Glc: GalA: GlcA = 19.2:2.1:9.6:12:15.2:11.5:26.3:4.1 | |||
| AGC3 | seed | 4.81 × 103 3.214 × 104 | acidic | Ara: Rha: Glc: Gal: GalA: GluA = 7.8: 8.1: 2: 74.3: 6.8: 1 | pectic rhamnogalacturonan I polysaccharide | [ | |
| PPQA2 | root | 2.3 × 104 | acidic | Ara: Rha: Man: Gal: Glc: GalA: GlcA = 8.0:4.0:2.9:7.2:12.5:26.6:38.8 | homogeneous polysaccharides contained O-acetyl groups | [ | |
| PPQA4 | root | 1.2 × 105 | acidic | Ara: Rha: Man: Gal: Glc: GlcA = 19.7:5.1:8.1:23.9:41.3:2.0 | homogeneous polysaccharides | ||
| PPQA5 | root | 5.3 × 103 | acidic | Ara: Rha: Man: Gal: Glc: GalA: GlcA = 8.5:3.2:5.3:10.8:32.4:15.5:24.4 | homogeneous polysaccharides contained O-acetyl groups | ||
| AEP-2 | root | acidic | Ara: Man: Gal: Glc: GalA = 1.03:0.76:1.68:3.02:3.65 | contain in excess of 80% (by weight) poly-furanosyl-pyranosyl-saccharides | [ | ||
| PPN | root | [ | |||||
| PF3111 | root | 6.85 × 105 | Gal: Glc: Man: Ara: Xyl = 3.5:10.8:3.5:1.0:2.3 | heteroglycans | [ | ||
| PF3112 | root | 3.7 × 104 | Gal: Glc: Man: Ara: Xyl = 2.9:5.3:2.8:1.0:2.1 | ||||
| PBGA11 | root | 4.5 × 104 | Gal: Glc: Man: Ara: Xyl = 3.1:4.2:5.3:1.0:3.2 | ||||
| PBGA12 | root | 7.60 × 105 | Gal: Glc: Man: Ara: Xyl = 2.5:7.2:4.3:1.0:8.1 | ||||
| PNPS-0.3 | residue | 7.6655 × 104 | acidic | Rha: Ara: Gal: Glc: N-Acetyl-D-Glc: GalA = 15.5:25.2:33.3:4.5:4.4:17.1 | mainly consisted of a backbone of →4)- α-D-GalAp-(1 → 4-β-L-Rhap-1 → 4)-β-D- Galp-(1 → residues, with an α-L-Araf-1 → 5)-α-L-Araf-(1 → branch connecting to the backbone at O-3 of →4-β-L-Rhap-1 → | [ | |
| 1MD3-G2 | root | 1.14 × 106 | Rha: Ara: Xyl: Gal: GalA = 2: 14: 29: 45: 10 | with a slightly higher content of 4-galactan and HGA, and a lower content of arabinan. | [ | ||
| 1MD3-G3 | root | 2.8 × 105 | acidic | Rha: Ara: Xyl: Gal: GalA: GlcA = 2: 12: 41: 26: 16: 3 | a much lower content of galactan and arabinan, but higher amounts of GAX and HGA. | ||
| PSPJ | rhizome | 3.98 × 104 | neutral | Glc: Gal: Rha: Ara: Xyl: GalA: GlcA = 53.41: 13.62: 1.1: 0.99: 0.82: 25.02: 5.03 | 4-O-linked α-D-galacturonic acid, (1→4)-linked-α-D-galacturonic acid, 1, 3-linked β-D-galactose | [ | |
| PJPS | rhizome | neutral | Ara: Glc: Gal | heteropolysaccharide containing pyranose ring | [ |
Effects and Mechanisms of Polysaccharides From Panax Species
| Name | Methods | Models | Effects | pathways | Endotoxin test | Ref. | |
|---|---|---|---|---|---|---|---|
| WGFPN | RAW264.7 macrophage cells | NO (+), TNF-α (+), IL-6(+), IL-1β (+), IFN-γ (+), phagocytic index (+) | phagocytosis | Yes | [ | ||
| cyclophosphamide (CTX)-induced immunosuppressed mice | body weight (+), spleen indices (+), thymus indices (+), abolish the inhibition effect of CTX on the phagocytic uptake capacity of macrophage | ||||||
| WGPN | Sarcoma-180 (S180) tumor-bearing mice | spleen weights (+), lymphocyte proliferation (+), NK cell activity (+), NO (+), TNF-α (+), phagocytic index (+) | phagocytosis | [ | |||
| FGWP | RAW264.7 macrophage cells | IL-6 (+), IL-12 (+), TNF-α (+), FGEP-CA ≥ FGEP-A > FGEP-C > FGWP | Yes | [ | |||
| FGEF-C | |||||||
| FGEF-A | |||||||
| FGEF-CA | cyclophosphamide (Cy)-induced BALB/c mice | spleen indices (+), thymus indices (+) | |||||
| RGP1 | RAW 264.7 macrophage cells | NO (+), TNF-α (+), neutral red phagocytosis (+) | Yes | [ | |||
| RGP2-1 | |||||||
| NGP | murine BMDCs | IL-12 (+), phagocytosis (−), MHC II (+), CD80 (+), CD86 (+), CD83 (+), CD40 (+), IL-12p70 (+), TNF-α (+), T cell proliferation (+) | DCR, DC-CD4+T cell pathway | Yes | [ | ||
| GPNE-I | spleen cells | lymphocyte proliferation (+), GPNE-I > GPNE-II | [ | ||||
| GPNE-II | |||||||
| GS-P | SPF BALB/c mice (immunized with OVA, OVA + GS-P, OVA + FCA, OVA + FIA, OVA + FIA + GS-P) | IL-12 (+), TNF-α (+), IgG1 (+), IgG2b (+), Th1-type (IL-2, IFN-γ, GM- CSF) (+), Th2-type (IL-10) (+), T cell proliferation (+), IgE (−) | Yes | [ | |||
| Splenic lymphocytes and macrophages from BALB/c mice | IL-12 (+), TNF-α (+), splenocytes proliferation | [ | |||||
| BALB/c mice | NK cell activity (+) | ||||||
| GFP1 | LLC-bearing mouse model | spleen and thymus weight (+), lymphocytes proliferation (+), NK cell activity (+), IL- 2 (+), IFN-γ (+), the ratio of CD4+/CD8+ (+) | Yes | [ | |||
| WGPA-2-RG | normal mice spleens, macrophages | lymphocytes proliferation (+), NO (+), phagocytosis (+) | Yes | [ | |||
| WGPA-UH-N1 | male ICR mice spleens, macrophages | B cell proliferation (+), NO (+) | [ | ||||
| RG-CW-EZ-CP-8 | Balb/c and C3H/He female mice macrophages, Peyer's patches | BM cell proliferation (+), IL-6 (+), GM-CSF (+), NO (+), TNF-α (+), IL-12 (+), RG-CW-EZ-CP-8> RG-CW-EZ-CP-4 | PRRs | [ | |||
| RG-CW-EZ-CP-4 | |||||||
| RGAP | mice peritoneal macrophages | NO (+), IL-6(+), IL-1(+), TNF-α (+), | NF-κB pathway | Yes | [ | ||
| ovariectomized rats | NK cells activity (+), iNOS (+), | Yes | [ | ||||
| RAW264.7 cells | NO (+), iNOS mRNA (+), NF-κB, AP-1, STAT-1, ATF-2, and CREB | TLR2, TLR4, Dectin-1, NF-κB, AP-1, EPK, JNK, | [ | ||||
| female BALB/c mice macrophage, spleen cell | iNOS (+), CD3CD4, CD3CD8, CD45R/B220 (−), CD11b (+) | [ | |||||
| Ginsan | BALB/c mice Sepsis model, peritoneal macrophages | TNF-α (+), IL-1β (+), IL-6 (+), IFN-γ (+), IL-12 (+), IL-18 (+), IL-10 (−), phagocytosis (+) | TLR 2, CR, SR, JNK, P38 MAPK, NF-κB | [ | |||
| C57BL/6 mice bone marrow-derived DCs | IL-12 (+), IL-10 (+), TNF-α (+), CD86 (+), CD4+ T lymphocytes proliferation (+), IL-4 (+), IFN-γ (+) | DC-CD4+T cell pathway | Yes | [ | |||
| APG | SJL/J Mice EAE | IFN-γ (+), IL-17 (+), TNF-α (+), T cell proliferation (+) | [ | ||||
| C57BL/6 female mice EAE | IFN-γ (+), IL-17 (+), IL-1β (+), CD25+ cells (−), Tregs (+), Foxp3 (+) | TLR, TCR, Foxp3 | [ | ||||
| GMP | BALB/c mice peritoneal macrophages | lysosomal phosphatase activity (+), phagocytic index (+), H2O2 (+), nitrite (+), cell viability (+) | lysosomal enzyme activity, phagocytosis | Yes | [ | ||
| PGP-SL | murine spleen lymphocytes | lymphocyte proliferation (+), IL- 2 (+), IL-2 mRNA (+), Ca2+ (+) | TCR/CD3, | [ | |||
| PPQ | Lewis lung carcinoma model in C57BL/6 mouse | thymus and spleen indices (+), IFN-γ (+), IL-10 (−), IL-2 (+) | Th1 response | [ | |||
| AGC1 | RAW 264.7 murine macrophages | IL-6, TNF-α, MCP-1, GM-CSF, NOS2 gene expression, iNOS, NO, cell proliferation, complement fixation activity | TLRs, CR, SR, lectin receptors, | Yes | [ | ||
| PPQN | RAW264.7 macrophages | NO (+), TNF-α (+), IL-6(+), IL-1β (+) | [ | ||||
| WPS-1 | male Jilin mice | B cell proliferation (+), phagocytosis: SPS-3> SPS-1, NO: SPS-3 > SPS-1 > WPS-1 >WPS-2, SPS-3 > SPS-1> WPS-1> WPS-2 > SPS-2 | [ | ||||
| WPS-2 | |||||||
| SPS-1 | |||||||
| SPS-2 | |||||||
| SPS-3 | |||||||
| AGC3 | RAW264.7 murine macrophage cells | IL-6 (+), TNF-α (+), GM-CSF (+), MCP-1(+), IL-10 (+), NO (+), primary murine splenocyte proliferation | TLR, NOD2, C-type lectin, NF-κB (p65/RelA), MAPK (p38) pathways | Yes | [ | ||
| PPQA2 | RAW264.7 murine macrophages | IL-6 (+), TNF-α (+), NO (+) | [ | ||||
| PPQA4 | |||||||
| PPQA5 | |||||||
| AEP-2 | RAW264.7 cells | IL-6 (+), TNF-α (+), NO (+), lymphocyte proliferation (+) | [ | ||||
| PPN | H22 tumor-bearing mice | CD4+ T-cells (+), IL-2 (+), | DC-CD4+T cell pathway | Yes | [ | ||
| PF3111 | mouse peritoneal macrophages | anticomplementary activity: PBGA12> PF3112, IFN-γ (+), TNF-α (+) | classical and alternative pathway | [ | |||
| PF3112 | |||||||
| PBGA11 | |||||||
| PBGA12 | |||||||
| PNPS-0.3 | BALB/c mice BMDCs and T cells | CD40 (+), CD80 (+), CD86 (+), MHC II (+), TNF-α (+), IL-12 (+), CD4 (+), CD8 (+), CD69 (+), INF-β (+) | TLR 4, TLR 2, and MR TLR4/TLR2-NF-κB pathway | Yes | [ | ||
| 1MD3-G2 | Human PMNs/PBMC | complement-fixing activity | Yes | [ | |||
| 1MD3-G3 | |||||||
| PSPJ | mice bearing H22 hepatoma cells | thymus/spleen indexes (+), splenocyte proliferation (+), NK and CD8+ T cells cytotoxic activities (+), TGF-β (−), IL-10 (−), PEG2 (−), M2-like polarization of TAMs (−), IFN-γ (+), IL-2 (+), IL-4 (−), | COX-2/PGE2 signaling pathway | Yes | [ | ||
| PJPS | kunming mice | phagocytosis (+), IgM (+), auricle swelling degree (+), thymus index (+), spleen index (+) | Yes | [ |
Fig. 1Signaling pathways on macrophages activated by Panax polysaccharides.
Fig. 2Signaling pathways on DC activated by Panax polysaccharides.